Urologix (Urologix) Cash per Share : $0.02 (As of Mar. 2015)

View and export this data going back to 1996. Start your Free Trial

What is Urologix Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Urologix's Cash per Share for the quarter that ended in Mar. 2015 was $0.02.

Urologix Cash per Share Historical Data

The historical data trend for Urologix's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Urologix Cash per Share Chart

Urologix Annual Data

Trend

Jun05

Jun06

Jun07

Jun08

Jun09

Jun10

Jun11

Jun12

Jun13

Jun14

Cash per Share

Get a 7-Day Free Trial

0.40

0.21

0.13

0.11

0.03

Urologix Quarterly Data
	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15
Cash per Share	Get a 7-Day Free Trial															0.04	0.03	0.03	0.03	0.02

Urologix Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Urologix's Cash per Share for the fiscal year that ended in Jun. 2014 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	0.718	/	20.95
	=	0.03

Urologix's Cash per Share for the quarter that ended in Mar. 2015 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	0.492	/	21.28
	=	0.02

Urologix (OTCPK:ULGX) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Urologix Cash per Share Related Terms

Thank you for viewing the detailed overview of Urologix's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Urologix (Urologix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Urologix Inc (OTCPK:ULGX) » Definitions » Cash per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

14405 21st Avenue North, Suite 110, Minneapolis, MN, USA, 55447

Website

http://www.urologix.com

Urologix Inc is a United States-based company engaged in the development, manufacturing, and marketing of minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). The firm markets the Cooled ThermoTherapy (CTC) product line and the Prostiva Radio Frequency (RF) Therapy System (Prostiva). The CTC produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. The Prostiva delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH voiding symptoms. The CTC product line includes the CoolWave and Targis Control Units and the CTC Advance catheter.

Executives

Emery Sidney W Jr	director	C/O QUALIGEN THERAPEUTICS, INC., 2042 CORTE DEL NOGAL, CARLSBAD CA 92011
Patrick D Spangler	director	14405 21ST AVENUE NORTH, MINNEAPOLIS MN 55447
Gregory Fluet	director, officer: CEO	14405 21ST AVENUE NORTH, MINNEAPOLIS MN 55447
William M Moore	director
Guy C Jackson	director	C/O EPICEPT CORPORATION, 777 OLD SAW MILL ROAD, TARRYTOWN NY 10591
Daniel J Starks	director	ONE ST JUDE MEDICAL DRIVE, ST PAUL MN 55117
Claude Tihon	officer: Chief Technology Officer
Bobby Ivan Griffin	director	1326 SPRING VALLEY RD GOLDEN VALLEY PA 55422
David A Montecalvo	officer: VP, Product Dev. & Operations	530 HERMAN O. WEST DRIVE, EXTON PA 19341
Susan Bartlett Foote	director	649 SUMMIT AVENUE, ST PAUL MN 55105